Published in Hepatology on October 01, 2008
Cholangiocarcinoma. Lancet (2014) 4.52
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol (2015) 1.58
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver (2009) 1.43
The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int (2014) 1.25
The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol (2012) 1.13
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. Br J Cancer (2012) 1.02
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
New insights on cholangiocarcinoma. World J Gastrointest Oncol (2010) 0.94
Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology (2012) 0.93
A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer (2011) 0.92
Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol (2011) 0.89
Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis (2012) 0.88
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep (2015) 0.87
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology (2015) 0.87
Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion (2014) 0.84
How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed? Viszeralmedizin (2015) 0.84
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol (2015) 0.82
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol (2016) 0.82
Advanced therapeutic endoscopist and inflammatory bowel disease: dawn of a new role. World J Gastroenterol (2014) 0.81
Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford) (2011) 0.81
Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer (2012) 0.81
Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist. World J Hepatol (2015) 0.80
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Med Sci Monit (2015) 0.80
The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells. Sci Rep (2015) 0.79
Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2015) 0.78
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc (2016) 0.78
Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterol Res Pract (2016) 0.78
Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis. Gastroenterol Res Pract (2016) 0.77
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology (2017) 0.77
Screening and surveillance for occupational cholangiocarcinoma in workers exposed to organic solvents. Surg Today (2015) 0.76
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
Preneoplastic conditions underlying bile duct cancer. Langenbecks Arch Surg (2012) 0.75
Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry. Cancers (Basel) (2010) 0.75
Advanced endoscopic imaging of indeterminate biliary strictures. World J Gastrointest Endosc (2015) 0.75
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75
Biochemical profile of bile fluid in patients with malignant cholestasis in comparison with cholestasis due to gall stone. Caspian J Intern Med (2015) 0.75
Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. Dig Dis Sci (2016) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med (2007) 3.55
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol (2009) 2.64
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology (2004) 2.35
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology (2006) 2.02
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem (2006) 2.00
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer (2002) 1.60
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med (2012) 1.56
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol (2003) 1.50
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med (2007) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43
Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol (2010) 1.37
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.11
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol (2008) 1.10
The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn (2006) 1.09
False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors. Gut (2010) 1.09
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology (2009) 1.09
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol (2005) 1.09
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol (2005) 1.07
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease. Dysphagia (2009) 1.06
The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol (2005) 1.05
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol (2007) 1.03
Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol (2011) 1.02
Interlaboratory comparison of IDH mutation detection. J Neurooncol (2013) 1.02
Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis (2006) 1.02
A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med (2013) 1.01
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol (2003) 1.00
Evaluating sex and gender competencies in the medical curriculum: a case study. Gend Med (2012) 1.00
Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res (2006) 1.00
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 0.99
Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol (2009) 0.99